DGI:Opportunistische Infektionen/CMV/Quellen: Unterschied zwischen den Versionen

Aktuelle Version vom 4. August 2026, 11:07 Uhr

Robert Koch-Institut. RKI-Ratgeber Zytomegalievirus-Infektion. Stand 24.10.2023.
Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900–931.
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients – Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512.
Limaye AP, Budde K, Humar A, et al. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA. 2023;330(1):33–42.
Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017;377(25):2433–2444.
Avery RK, Alain S, Alexander BD, et al. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial (SOLSTICE). Clin Infect Dis. 2022;75(4):690–701.
Papanicolaou GA, Avery RK, Cordonnier C, et al. Maribavir versus Valganciclovir for First CMV Infection Post-Hematopoietic Cell Transplant (AURORA). Clin Infect Dis. 2024;78(3):562–572.
Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation (ECIL-7). Lancet Infect Dis. 2019;19(8):e260–e272.
Fryer JF, Heath AB, Minor P, et al. A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. Biologicals. 2016;44(4):242–251.

@@ Zeile 1: / Zeile 1: @@
-https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Zytomegalievirus.html;jsessionid=13FA88DA454E7CD74309C4050B66B0D2.internet082#doc4738494bodyText10
-https://www.uniklinikum-saarland.de/fileadmin/UKS/Einrichtungen/Kliniken_und_Institute/Infektionsmedizin/Prof_Transplantation/Diagnostik/2019_Schmidt_Sester_CME_CMV.pdf
+* Robert Koch-Institut. RKI-Ratgeber Zytomegalievirus-Infektion. Stand 24.10.2023.
-https://www.dgho.de/publikationen/stellungnahmen/fruehe-nutzenbewertung/copy_of_letermovir/letermovir-dgho-dag-kbt-stellungnahme-20180605.pdf
+* Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102(6):900–931.
-Brodt, Hans Reinhardt: Stille Antibiotika Therapie, Klinik und Praxis der antiinfektiösen Behandlung. 2 Auflage.
+* Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients – Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512.
-Hoffmann C. & Rockstroh, J.: HIV 2020/ 2021. www.hivbuch.de
+* Limaye AP, Budde K, Humar A, et al. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA. 2023;330(1):33–42.
-Dante P Melendez and Raymund R Razonable: Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus; Infect Drug Resist. 2015; 8: 269–277. Published online 2015 Aug 5. doi: 10.2147/IDR.S79131 PMCID: PMC4531042
+* Marty FM, Ljungman P, Chemaly RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017;377(25):2433–2444.
-https://next.amboss.com/de/article/nf0752#Z33d59c26da10cb6030670c9557deb5e5
+* Avery RK, Alain S, Alexander BD, et al. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial (SOLSTICE). Clin Infect Dis. 2022;75(4):690–701.
-https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431500/
+* Papanicolaou GA, Avery RK, Cordonnier C, et al. Maribavir versus Valganciclovir for First CMV Infection Post-Hematopoietic Cell Transplant (AURORA). Clin Infect Dis. 2024;78(3):562–572.
-Munro M, Yadavalli T, Fonteh C, Arfeen S, Lobo-Chan AM: Cytomegalovirus Retinitis in HIV and Non-HIV Individuals. Microorganisms. 2019 Dec 28;8(1):55. doi: 10.3390/microorganisms8010055.
+* Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation (ECIL-7). Lancet Infect Dis. 2019;19(8):e260–e272.
-https://www.awmf.org/uploads/tx_szleitlinien/093-002l_S2k_Virusinfektionen-Organtransplantierte-alloge-Stammzell-Transplantierten-Diagnostik-Praevention-Therapie__2019-06.pdf
+* Fryer JF, Heath AB, Minor P, et al. A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. Biologicals. 2016;44(4):242–251.
-https://www.aerzteblatt.de/nachrichten/126064/CMV-Hyperimmunglobulin-kann-Fetopathie-in-der-Schwangerschaft-nicht-verhindern
-https://www.nejm.org/doi/full/10.1056/NEJMoa1913569